Andrographolide AD - InnoBioscience
Alternative Names: Andrographolide AD InnoBioscience; Andrographolide Alzheimer's disease InnoBioscience; IB-ADLatest Information Update: 28 Apr 2022
At a glance
- Originator InnoBioscience
- Class Anti-inflammatories; Antidementias; Antifibrotics; Antineoplastics; Naphthalenes; Small molecules
- Mechanism of Action Beta catenin stimulants; Cell cycle inhibitors; Connective tissue growth factor inhibitors; Glycogen synthase kinase 3 beta inhibitors; NF-kappa B kinase inhibitors; Nitric oxide inhibitors; Phospholipase C inhibitors; Protein kinase C inhibitors; Wnt signalling pathway stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 28 Apr 2022 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA (PO)
- 25 Feb 2019 Andrographolide (IB AD) is still in preclinical trials for Alzheimer's disease in USA
- 25 Feb 2019 Andrographolide AD - InnoBioscience is available for licensing as of 29 Mar 2018. http://www.innobioscience.com